1. Home
  2. WGS vs QURE Comparison

WGS vs QURE Comparison

Compare WGS & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

HOLD

Current Price

$65.62

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo uniQure N.V.

QURE

uniQure N.V.

HOLD

Current Price

$43.49

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WGS
QURE
Founded
2017
1998
Country
United States
Netherlands
Employees
1300
248
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
WGS
QURE
Price
$65.62
$43.49
Analyst Decision
Strong Buy
Buy
Analyst Count
7
14
Target Price
$120.71
$45.00
AVG Volume (30 Days)
1.0M
2.9M
Earning Date
05-04-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.67
EPS
N/A
N/A
Revenue
N/A
$13,107,000.00
Revenue This Year
$29.98
$126.12
Revenue Next Year
$25.92
$200.43
P/E Ratio
$1,251.58
N/A
Revenue Growth
N/A
N/A
52 Week Low
$32.21
$8.73
52 Week High
$170.87
$71.50

Technical Indicators

Market Signals
Indicator
WGS
QURE
Relative Strength Index (RSI) 55.31 59.95
Support Level $55.76 $22.20
Resistance Level $73.46 $50.47
Average True Range (ATR) 4.39 3.47
MACD 0.02 -0.81
Stochastic Oscillator 56.54 27.89

Price Performance

Historical Comparison
WGS
QURE

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

About QURE uniQure N.V.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

Share on Social Networks: